Human Insulin Market Size Future Growth And Forecast With Significant Players 2019 - 2027
Human Insulin Market to Benefit from the Development of
Biosimilars:
With the global prevalence of diabetes expanding
significantly, the global human
insulin market Size is expected to grow at a compound annual growth rate of
12.5% over the forecast period of 2017-2023, proclaims Market Research Future
(MRFR) in a meticulously analyzed research report. Change in lifestyle and high
prevalence of obesity is the root cause of widespread occurrence of diabetes
which induces demand for human insulin. The rise in the global geriatric
population who are at more risk of suffering from diabetes coupled with raising
awareness of diabetes boosts the growth of the global human insulin market.
Growing emphasis on diabetes management and technological advancement of
insulin delivery devices such as the introduction of insulin pens have added
fuel to ten growth of the market. The rise in a number of clinical trials for
the development of novel therapies and treatment for diabetes purveyed by
investment from pharmaceuticals companies has been a plus for the market
growth. However, the soaring price of human insulin, manufacturing complexities
and complicated regulatory process for the approval of new drugs impede the
growth of the market. Additionally, loss of patent acts as a major deterrent to
the market growth. Development of biosimilars is a significant trend which is
expected to increase the competition in the market and in turn, boost the
market growth
Get Sample Report: https://www.marketresearchfuture.com/sample_request/951
Segmentation
The global human insulin market has been segmented based on
type, methods, indication, and end users. By type, the market has been
segmented into accessories and devices. By methods, the market has been
segmented into traditional human insulin and modern human insulin. By
indication, the market has been segmented into type 1 diabetes and type 2
diabetes. By end users, the market has been segmented into hospitals, forensic
laboratories, research centers, and others.
Regional Analysis
The global human insulin market spans across the regions of
the Americas, Europe, Asia Pacific, and the Middle East & Africa. North
America accounts for the largest share of the global human insulin market owing
to high health care spending, the presence of major players in the region who
invest more money in R&D activities and inclination towards quality
healthcare. The US is the largest market in the region followed by Canada while
South America is expected to be the fastest growing region. The Europe market
for human insulin is strong and is driven by the presence of a large pool of
patients and the availability of funds for research and development in
countries such as Germany. Asia Pacific market growth is supported by the
presence of a vast patient base and rising prevalence of diabetes in the
region. Improvement in healthcare infrastructure in countries such as China,
India, and Japan is key to the growth of the market. Moreover, Asia Pacific
hosts a huge geriatric population who are at more risk of acquiring diabetes.
The Middle East & Africa market is expected to exhibit steady growth over
the forecast period. Countries such as United Arab Emirates (U.A.E.), Saudi
Arabia, and Oman have a robust healthcare infrastructure which drives the market
in the Middle East while in Africa, weak economic conditions and
under-developed healthcare sector deters the growth of the market.
Competitive Landscape
The notable players operating in the global human insulin
market include Biocon Ltd, ADOCIA, Julphar, Bristol-Myers Squibb Company,
Oramed Pharmaceuticals, Inc, Sanofi, Tonghua Dongbao Pharmaceuticals Co., Ltd.,
Merck & Co, Pfizer, Inc, GlaxoSmithKline, and Novo Nordisk A/S.
Access Report@ https://www.marketresearchfuture.com/reports/human-insulin-market-one-849
Industry Updates
In August 2018, Monarch Medical Technologies, a leading
provider of electronic systems for inpatient glycemic management received US
patent for its approach to inpatient insulin therapy. The approach has already
been granted class II FDA clearance and underlines the uniqueness of the
EndoTool technology.
About US:
Market Research Future (MRFR) enable customers to unravel
the complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
Comments
Post a Comment